PLx Pharma (FRA:1D5A) Total Equity : €26.46 Mil (As of Sep. 2022)

View and export this data going back to 2014. Start your Free Trial

What is PLx Pharma Total Equity?

PLx Pharma's total equity for the quarter that ended in Sep. 2022 was €26.46 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

PLx Pharma Total Equity Historical Data

The historical data trend for PLx Pharma's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PLx Pharma Total Equity Chart

PLx Pharma Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Total Equity

Get a 7-Day Free Trial

3.90

5.66

1.41

8.59

45.74

PLx Pharma Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Total Equity	Get a 7-Day Free Trial															39.87	45.74	38.12	30.75	26.46

PLx Pharma Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

PLx Pharma's Total Equity for the fiscal year that ended in Dec. 2021 is calculated as

Total Equity	=	Total Assets(Q: Dec. 2021 )	-	Total Liabilities(Q: Dec. 2021 )
	=	67.828	-	22.091
	=	45.74

PLx Pharma's Total Equity for the quarter that ended in Sep. 2022 is calculated as

Total Equity	=	Total Assets(Q: Sep. 2022 )	-	Total Liabilities(Q: Sep. 2022 )
	=	33.556	-	7.093
	=	26.46

PLx Pharma Total Equity Related Terms

Thank you for viewing the detailed overview of PLx Pharma's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

PLx Pharma (FRA:1D5A) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PLx Pharma Inc (FRA:1D5A) » Definitions » Total Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

8 The Green, Suite 11895, Dover, DE, USA, 19901

Website

https://www.plxpharma.com

PLx Pharma Winddown Corp Formerly PLx Pharma Inc is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard drug delivery platform designed to provide more effective and safer products. The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the GI tract. It believes this platform has the potential to improve the absorption of many drugs currently on the market or in development and to reduce the risk of stomach erosions and ulcers associated with drugs. VAZALORE is a novel formulation of aspirin clinically shown to provide fast, reliable and predictable platelet inhibition for patients with vascular disease and diabetic patients who may be candidates for aspirin therapy.

PLx Pharma (FRA:1D5A) Headlines

No Headlines